Diabetes Therapy
Insulin-receptor sensitizer developer provides corporate update
Published in Obesity and Diabetes Week, September 15th, 2003
[helv]During the year ended March 31, 2003, the company decided to fully focus its management and capital resources on the development of markets for Sucanon, the company's type II diabetes treatment. Accordingly, the company closed its lotions and creams operation, sharply reducing ongoing overhead costs and monthly losses. Simultaneously, with the sale of equipment related to the lotions and creams operation, the company's secured debt has been reduced by $1.5 million.
The company...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Obesity and Diabetes Week
More Articles from Obesity and Diabetes Week
- Bone Mineral Density
Healthy weight and exercise maintains bone mineral density late in life - Insulin Resistance
Insulin resistance syndrome increases risk of coronary artery disease - Complementary and Alternative Medicine
Mechanism by which chromium picolinate may enhance insulin sensitivity revealed - Diabetes Therapy
Blood pressure and lipid treatment guidelines in diabetic patients discussed - Obesity Epidemiology
High prevalence of Ala54Thr FABP2 polymorphism high in Tongans - Reproductive Medicine
Weight loss may help resolve reproductive disorders in obese women - More from this issue of Obesity and Diabetes Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
